GlassScriptPhysician profile
Danielle E Etzkorn
NPI 1982284410
$3,578.79
in general payments reported to CMS, 2019-2025
25 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $354 · 2023: $1,051 · 2024: $1,144 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $650.71 | 2022-2025 | Mounjaro, Zepbound, Basaglar |
| Pfizer INC. | $637.17 | 2023-2025 | |
| Amgen INC. | $515.47 | 2022-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $390.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $210.45 | 2022-2025 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $145.08 | 2022-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.97 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $135.55 | 2024-2025 | Veozah |
| Vertex Pharmaceuticals Incorporated | $94.85 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $83.44 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.57 | 2022 | |
| Exact Sciences Corporation | $68.33 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $65.81 | 2025 | |
| Glaxosmithkline, LLC. | $60.99 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Medtronic, INC. | $41.51 | 2022-2024 | Minimed 780g |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.04 | 2022-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $36.03 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $31.65 | 2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $30.86 | 2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $28.31 | 2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $22.55 | 2022 | |
| Inspire Medical Systems, INC. | $19.52 | 2025 | Inspire |
| Dexcom, INC. | $18.31 | 2025 | Dexcom G6 Transmitter |
| Axonics, INC. | $17.71 | 2024 | Axonics |
| Solventum Corporation | $13.59 | 2024 | V.A.C.Ulta, Prevena, V.A.C. Dermatac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Etzkorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.